Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.60 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.56 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.56 |
| ▸ | PIK3CA known ✓ | P42336 | 2/20 | 0.48 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.60 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.58 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL75665 | 0.98 | CA2 (0.62) | CA2CAMK2AAKR1B1CTBP2LMNA | |
| Methane SCHEMBL1994900 | 0.95 | CA2 (0.60) | CA2CAMK2AAKR1B1CTBP2LMNA | |
| SCHEMBL28038880 | 0.95 | CA2 (0.60) | CA2CAMK2AAKR1B1CTBP2LMNA | |
| SCHEMBL4211639 | 0.91 | ABCC4 (0.69) | CA2CAMK2AAKR1B1CTBP2LMNA | |
| SCHEMBL11830858 | 0.89 | CA2 (0.54) | CA2CAMK2AAKR1B1CTBP2LMNA | |
| Hydrochloric Acid SCHEMBL25180348 | 0.87 | CA2 (0.75) | CA2CAMK2AAKR1B1LMNAABCC4 | |
| Hydrochloric Acid SCHEMBL6765874 | 0.87 | CA2 (0.75) | CA2CAMK2AAKR1B1LMNAABCC4 | |
| SCHEMBL6441891 | 0.86 | SRD5A2 (0.62) | CA2CAMK2AFFAR1 | |
| SCHEMBL5465427 | 0.86 | PDE4B (0.53) | CA2CAMK2AAKR1B1CTBP2LMNA | |
| SCHEMBL11565077 | 0.86 | CYP26A1 (0.51) | CA2CAMK2AAKR1B1CTBP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662156-B2 | Guanidine derivative and medical use thereof | TORAY INDUSTRIES, INC. (JP) | 2020-05-26 | — | — | US | disclosed |
| US-20190233376-A1 | GUANIDINE DERIVATIVE AND MEDICAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2019-08-01 | — | — | US | disclosed |
| EP-3495348-A1 | GUANIDINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | Toray Industries, Inc. (JP) | 2019-06-12 | — | — | EP | disclosed |
| EP-1919857-B1 | PROCESS FOR THE SYNTHESIS OF MANDIPROPAMID AND DERIVATIVES THEREOF | SYNGENTA PARTICIPATIONS AG (CH) | 2016-03-09 | — | — | EP | disclosed |
| US-8129560-B2 | Process for the synthesis of mandipropamid and derivatives thereof | SYNGENTA CROP PROTECTION, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090118532-A1 | Process for the Synthesis of Mandipropamid and Derivatives Thereof | SYNGENTA CROP PROTECTION, INC. (US) | 2009-05-07 | — | — | US | disclosed |
| EP-1919857-A2 | PROCESS FOR THE SYNTHESIS OF MANDIPROPAMID AND DERIVATIVES THEREOF | Syngeta Participations AG (CH) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007038425-A2 | ANTI-VIRAL COMPOUINDS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007020381-A2 | PROCESS FOR THE SYNTHESIS OF MANDIPROPAMID AND DERIVATIVES THEREOF | SYNGENTA PARTICIPATIONS AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| US-20030114442-A1 | Substituted piperazine derivatives as mtp inhibitors | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-06-19 | — | — | US | disclosed |
| US-5919807-A | ANTICHOLESTEROL AGENTS | DR. KARL THOMAE GMBH (DE) | 1999-07-06 | — | — | US | disclosed |
| US-5147889-A | Antiinflammatory, analgesic | CIBA-GEIGY CORPORATION (US) | 1992-09-15 | — | — | US | disclosed |
| US-5051421-A | Analgesics and antiinflammatory agents | CIBA-GEIGY CORPORATION (US) | 1991-09-24 | — | — | US | disclosed |
| US-4639541-A | FUNGICIDES | CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH (DE) | 1987-01-27 | — | — | US | disclosed |
| US-4473560-A | Diphosphonic acid derivatives and pharmaceutical preparations containing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1984-09-25 | — | — | US | disclosed |
| US-4388246-A | THERMAL SPLITTING OF CARBAMATES | BAYER AKTIENGESELLSCHAFT (DE) | 1983-06-14 | — | — | US | disclosed |
| US-4349556-A | Pesticidally active 1-acyloxy-1-phenyl-2-azolyl-ethanes | BAYER AKTIENGESELLSCHAFT (DE) | 1982-09-14 | — | — | US | disclosed |
| US-4266066-A | FROM CARBOXYLIC ACYL HALIDE AND ALUMINUM ALKYL COMPOUNDS | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-05-05 | — | — | US | disclosed |
| US-4067726-A | 3-Ureido phenylacetamide herbicides | BAYER AKTIENGESELLSCHAFT (DT) | 1978-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114442-A1 | Substituted piperazine derivatives as mtp inhibitors | MTTP, CETP, LIPC | CA2 4433/4885GAA 622/4885PTGS1 877/4885 |
| US-20190233376-A1 | GUANIDINE DERIVATIVE AND MEDICAL USE THEREOF | MALT1, GUCY1A1, GUCY1B1 | CA2 924/4885GAA 30/4885PTGS1 121/4885 |
| US-10662156-B2 | Guanidine derivative and medical use thereof | MALT1, GUCY1A1, GUCY1B1 | CA2 924/4885GAA 30/4885PTGS1 121/4885 |
| US-20090118532-A1 | Process for the Synthesis of Mandipropamid and Derivatives Thereof | OPRM1, OPRD1, ADRA1D | CA2 568/4885GAA 3441/4885PTGS1 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.